A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease (PERIDOT)

Sanofi

Status and phase: Active, not recruiting; Phase 3

Conditions: Fabry Disease

Treatments: Drug: Placebo; Drug: Venglustat (GZ402671)

Study type: Interventional

Funder types: Industry

Identifiers

NCT05206773

U1111-1256-9310 (Registry Identifier)

EFC17045

2024-511990-31 (Registry Identifier)

2021-002350-90 (EudraCT Number)

Details and patient eligibility

About

This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age with Fabry disease who are treatment-naïve or untreated for at least 6 months.

• Study visits will take place approximately every 3 months.
• The double-blind period will be followed by an open-label extension (OLE) during which participants who have completed the double-blind period will be treated with venglustat for up to an additional 12 months.

Full description

Double blind period: the total duration will be up to approximately of 14 months (1 month of screening 12 month of treatment period, and a possible follow-up period of 1 month if no participation in the open label extension period)

Open-label extension period: the total duration will be approximately of 46 months (12 month of OLE treatment, additional OLE treatment until a common study end of treatment date (CSEOTD, approximately 33 months), and 1 month of follow-up period)

Enrollment: 122 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female adult patients 16 year of age or older, who have had a previously confirmed diagnosis of Fabry disease and a history of clinical symptoms of Fabry disease
• Patients who are treatment-naïve or without prior treatment with an approved or experimental therapy for Fabry disease within at least 6 months prior to screening.
• Average score of ≥3 (0=no symptom, 10=symptom as bad as you can imagine) on the participant-defined most-bothersome symptom (among neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain), as measured by the Fabry Disease Patient-Reported Outcome (FD-PRO) at screening.
• Contraception (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants.
• Weight ≥30 Kg
• A signed informed consent must be provided prior to any study-related procedures.

Exclusion criteria

• Any manifestations of Fabry disease that preclude placebo administration.
• History of transient ischemic attack, stroke, myocardial infarction, heart failure, evidence of left ventricular hypertrophy and/or cardiac fibrosis, major cardiovascular surgery, or kidney transplantation.
• History of clinically significant cardiac arrhythmia. Atrial fibrillation that is well controlled on a stable medical regimen for at least 12 months is not an exclusion if the CHA2DS2-VASc score is 0 for males or 1 for females.
• Patients with hepatitis C, HIV, or hepatitis B infection.
• Neuropathic pain in upper or lower extremities, or abdominal pain not related to Fabry disease.
• History of seizures currently requiring treatment.
• Uncontrolled hypertension over the past 12 months prior to screening, or systolic BP >=150 or diastolic BP >=100 at screening.
• Estimated glomerular filtration rate <60 mL/min/1.73m².
• Urine protein to creatinine ratio >= 1 g/g at screening.
• Presence of severe depression as measured by Beck's Depression Inventory (BDI)-II >28 and/or a history of an untreated, unstable major affective disorder within 1 year of the screening visit.
• Positive SARS-CoV-2 virus test within 2 weeks of enrollment, or COVID 19 requiring hospitalization within 6 months of enrollment.
• Moderate to severe hepatic impairment.
• History of drug and/or alcohol abuse.
• History of or active hepatobiliary disease.
• Liver enzymes (alanine aminotransferase (ALT)/aspartate aminotransferase (AST)) or total bilirubin >2 times the upper limit of normal (ULN).
• Initiation of chronic treatment for pain, or change in pain medication regimen, within 3 months prior to randomization.
• Strong or moderate inducers or inhibitors of cytochrome P450 3A within 14 days or 5 half-lives, whichever is longer, prior to randomization.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

122 participants in 2 patient groups, including a placebo group

Venglustat

Experimental group

Description:

Participant will receive venglustat dose once daily up to 12 months

Treatment:

Drug: Venglustat (GZ402671)

Placebo

Placebo Comparator group

Description:

Participants will receive placebo once daily up to 12 months

Treatment:

Drug: Placebo